NICE has updated Clinical Guideline (CG) 71 on Familial hypercholesterolaemia: identification and management. Familial hypercholesterolaemia (FH) is a genetic disorder characterised by high cholesterol levels from birth, putting affected individuals at increased risk of developing cardiovascular disease.
Following a review of current evidence on case finding, diagnosis, and statin monotherapy, NICE has made amendments to exisiting recommendations, and added new recommendations to the guideline. One notable change is that nicotinic acid no longer has a UK licence, and so any reference to it has been removed from the guideline. A full list of updated recommendations is available.
NICE CG71 makes recommendations on:
- diagnosis of FH
- identifying people with FH using cascade testing
- drug treatment, lifestyle interventions, and specialist treatment
- information and support on contraception for women with FH and for pregnant women with FH
- review and referral for evaluation of coronary heart disease.